Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: An observational study

Atherosclerosis

Volumn 185, Issue 1, 2006, Pages 58-64

  Van Ganse, E ^a   Souchet, T ^b   Laforest, L ^a   Moulin, P ^c   Bertrand, M ^d   Le Jeunne, P ^e   Chretin, S ^a   Yin, D ^f   Alemao, E ^f   De Pouvourville, G ^g  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Dohme Chibret Centre de Recherche Riom   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BKL   (France)

^f MERCK RESEARCH LABORATORIES   (United States)

^g INSERM   (France)

Author keywords

Cardiovascular diseases; Cohort; Dyslipidemia; General practitioners; Guidelines; Primary prevention

Indexed keywords

AMIODARONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OBSERVATION; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 31044449207     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.05.036     Document Type: Article

References (23)

1. J.R. Down, M. Clearfield, and S. Weis For the AFCAPS/Tex CAPS Research Group. Primary prevention of acute coronary with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
2. F.M. Sacks, M.A. Pfeffer, and L.A. Moyle For the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
3. The long-term intervention with pravastatin in ischemic disease (LIPID) study group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet 1994;334:1383-89.
5. J. Shepherd, S.M. Cobbe, and I. Ford For the West of Scotland coronary prevention study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
6. Heart Protection Study Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled group. Lancet 2002;360:7-22.
7. French Health Products Safety Agency Agence Française de Sécurité Sanitaire des Produits de Santé. Therapeutic management of dyslipidemic patient - September 2000.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 17;106:3143-421.
9. P. Primesta, and N.R. Poulter Lipid concentrations and the use of lipid lowering drugs: evidence from national cross-sectional survey MMJ 321 2000 1322 1325
10. P. Mc Bride, H.G. Schrott, M.B. Plane, and G. Underbakke Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disese Arch Intern Med 158 1998 1238 1244
11. Pearson, TA, Laurora, I, Chu, H, Kafonek, S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;28:160:459-67.
12. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554-72.
13. E. Van Ganse, T. Souchet, and L. Laforest Ineffectiveness of lipid-lowering therapy in primary care Br J Clin Pharmacol 59 2005 456 463
14. M.K. Ito, G.M. Delucca, and M.A. Aldridge The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events J Cardiovasc Pharmacol Therapeut 6 2001 129 135
15. D.E. Hilleman, M.S. Monaghan, and C.L. Ashby Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease Pharmacotherapy 21 11 2001 1415 1421
16. T. Walley, P. Folino-Gallo, U. Schwabe, and E. van Ganse EuroMedStat group. Variations and increase in use of statins across Europe: data from administrative databases BMJ 14 328 2004 385 386
17. Folino P. Urbanization and health. New challenges to health promotion and prevention. EUPHA book 2005. In: Gunnar Tellnes, editor. Can we assess the impact of medicine utilization on population health? The example of statins utilization and Coronary Heart Disease mortality.
18. J. Hippisley-Cox, R. Cater, M. Pringle, and C. Coupland Cross-sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices BMJ 29 326 2003 689
19. H. Kanstrup, J.F. Lassen, L. Heickendorff, and T. Lauritzen Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients J Intern Med 255 2004 367 372
20. M. van Dam, S. van Wissen, and J.J. Kastelein Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol J Cardiovasc Risk 9 2002 89 95
21. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 3 291 2004 1071 1080
22. J.H. Okeefe, L. Cordain, W.H. Harris, and R.M. Moe Optimal low-density lipoprotein is 50 to 70 mg/dl - Lower is better and physiologically normal J Am College Cardiol 43 2004 2142 2146
23. C.P. Cannon, E. Braunwald, and C.H. McCabe Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504